Vertex Pharmaceuticals (VRTX) Interest Expenses (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Interest Expenses of $420.3 million for Q1 2026, up 17.6% year-over-year from $357.4 million in Q1 2025, and up 691.53% quarter-over-quarter from $53.1 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Interest Expenses (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $420.3 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 17.6% year-over-year to $420.3 million; the TTM figure through Mar 2026 stood at $420.3 million (up 17.6% YoY), while the FY2025 annual figure was $436.6 million, up 27.89% from the prior year.
- Interest Expenses for Q1 2026 stood at $420.3 million, up from $53.1 million in the prior quarter.
- The five-year high for Interest Expenses was $2.8 billion in Q3 2024, with the low at $11.0 million in Q4 2023.
- The 5-year median for Interest Expenses is $245.4 million (2023), against an average of $369.1 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 1038.88% in 2024, then plunged 84.91% in 2025.
- Vertex Pharmaceuticals' Interest Expenses stood at $13.7 million in 2022, then retreated by 19.71% to $11.0 million in 2023, then surged by 122.73% to $24.5 million in 2024, then surged by 116.73% to $53.1 million in 2025, then surged by 691.53% to $420.3 million in 2026.
- Business Quant data shows VRTX's Interest Expenses at $420.3 million in Q1 2026, $53.1 million in Q4 2025, and $421.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 439.40 Mn |
| Jun 30, 2026 | 439.40 Mn |
| Mar 31, 2026 | 420.30 Mn |
| Mar 31, 2026 | 420.30 Mn |
| Dec 31, 2025 | 53.10 Mn |
| Dec 31, 2025 | 53.10 Mn |
| Sep 30, 2025 | 421.60 Mn |
| Sep 30, 2025 | 421.60 Mn |
| Jun 30, 2025 | 412.10 Mn |
| Jun 30, 2025 | 412.10 Mn |
| Mar 31, 2025 | 357.40 Mn |
| Mar 31, 2025 | 357.40 Mn |
| Dec 31, 2024 | 24.50 Mn |
| Dec 31, 2024 | 24.50 Mn |
| Sep 30, 2024 | 2.79 Bn |
| Sep 30, 2024 | 2.79 Bn |
| Jun 30, 2024 | 309.30 Mn |
| Jun 30, 2024 | 309.30 Mn |
| Mar 31, 2024 | 301.60 Mn |
| Mar 31, 2024 | 301.60 Mn |